TABLE 1

Main characteristics of patients included in the study

Subjects218
Sex
 Male163 (74.8)
 Female55 (25.2)
Age at diagnosis years59.9±9.0
Weight loss percentage of usual weight
 ≤5%121 (55.5)
 >5% and ≤10%48 (22.0)
 >10%38 (17.4)
BMI categories at diagnosis
 Underweight (<18 kg·m²)18 (8.3)
 Normal weight (18–25 kg·m²)126 (57.8)
 Pre-obesity (25–30 kg·m²)56 (25.7)
 Obesity (>30 kg·m²)17 (7.8)
Histological subtype
 Adenocarcinoma147 (67.4)
 Squamous carcinoma43 (19.7)
 Large cell carcinoma28 (12.8)
Performance status at diagnosis
 085 (38.9)
 1128 (58.7)
 25 (2.3)
Stage at diagnosis
 Stage IV176 (80.7)
 Stage IIIB42 (19.3)
Platin drug
 Cisplatin185 (84.9)
 Carboplatin33 (15.1)
Doublet drug
 Vinorelbine25 (11.5)
 Pemetrexed39 (17.9)
 Paclitaxel28 (12.8)
 Gemcitabine78 (35.8)
 Docetaxel48 (22.0)
Bevacizumab use with CT11 (5.0)
Response category after platin-based chemotherapy (RECIST)
 Progressive disease35 (16.1)
 Stable disease132 (60.6)
 Partial response51 (23.4)
Number of chemotherapy line(s) after the first line (n=216)
 None45 (20.8)
 168 (31.5)
 257 (26.4)
 ≥346 (21.3)
  • Data are presented as n, n (%) or mean±sd. BMI: body mass index; CT: computed tomography; RECIST: response evaluation criteria in solid tumours.